| Literature DB >> 35598219 |
Sasi Kumar Jagadeesan1, Mustafa Al-Gafari1, Maryam Hajikarimlou1, Sarah Takallou1, Houman Moteshareie2, Azam Tayabali2, Bahram Samanfar3, Myron Smith1, Ashkan Golshani4.
Abstract
Lithium chloride (LiCl) is a widely used and extensively researched drug for the treatment of bipolar disorder (BD). As a result, LiCl has been the subject of research studying its toxicity, mode of action, and downstream cellular responses. LiCl has been shown to influence cell signaling and signaling transduction pathways through protein kinase C and glycogen synthase kinase-3 in mammalian cells. LiCl's significant downstream effects on the translational pathway necessitate further investigation. In yeast, LiCl is found to lower the activity and alter the expression of PGM2, a gene encoding a sugar-metabolism enzyme phosphoglucomutase. When phosphoglucomutase activity is reduced in the presence of galactose, intermediates of galactose metabolism aggregate, causing cell sensitivity to LiCl. In this study, we identified that deleting the genes PEX11 and RIM20 increases yeast LiCl sensitivity. We further show that PEX11 and RIM20 regulate the expression of PGM2 mRNA at the translation level. The observed alteration of translation seems to target the structured 5'-untranslated region (5'-UTR) of the PGM2 mRNA.Entities:
Keywords: Bipolar disorder; Cell sensitivity; Gene expression; Lithium chloride; Molecular toxicity; Translation; Yeast; mRNA
Year: 2022 PMID: 35598219 DOI: 10.1007/s11010-022-04466-5
Source DB: PubMed Journal: Mol Cell Biochem ISSN: 0300-8177 Impact factor: 3.396